Tezspire scores Phase 3 win in eosinophilic esophagitis, challenging Dupixent on August 27, 2026 Amgen AstraZeneca Deglutition Disorders dupilumab Dupixent Eosinophilic esophagitis Extra-osseous Ewing's sarcoma histologic remission tezepelumab Tezspire +